Distribution of LDL-C Reduction with Atorvastatin, Rosuvastatin and Simvastatin: A VOYAGER Meta-Analysis

被引：0
|
作者：
Karlson, Bjorn W. [1 ,2 ]
Palmer, Michael K. [3 ]
Nicholls, Stephen J. [4 ]
Lundman, Pia [5 ]
Barter, Philip J. [6 ]
机构：
[1] AstraZeneca, Molndal, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden
[3] Manchester Metropolitan Univ, Sch Healthcare Sci, Manchester M15 6BH, Lancs, England
[4] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[5] Karolinska Inst, Danderyd Hosp, Stockholm, Sweden
[6] Univ New S Wales, Sydney, NSW, Australia
来源：
CARDIOLOGY | 2015年 / 131卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-06
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [31] SYSTEMATIC REVIEW AND META-ANALYSIS ON THE DURATION AND MAGNITUDE OF LDL-C LOWERING AND MAJOR ADVERSE CARDIOVASCULAR EVENT REDUCTION
    Redel-Traub, Gabriel
    Smilowitz, Nathaniel
    Weintraub, Howard
    Schwartzbard, Arthur
    Berger, Jeffrey
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 7 - 7
  • [32] META-ANALYSIS OF ROSUVASTATIN VS ATORVASTATIN IN PATIENTS WITH CARDIOVASCULAR DISEASE
    Singh, Sahib
    Tantry, Udaya
    Bliden, Kevin
    Ishaq, Syed Muhammad Murtaza
    Abuzahra, Mohammed
    Gurbel, Paul A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1225 - 1225
  • [33] The DISCOVERY PENTA study:: a DIrect Statin COmparison of LDL-C value -: an Evaluation of Rosuvastatin therapY compared with atorvastatin
    Fonseca, FAH
    Ruiz, A
    Cardona-Muñoz, EG
    Silva, JM
    Fuenmayor, N
    Marotti, M
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (08) : 1307 - 1315
  • [34] Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with the metabolic syndrome: Results from the comets study
    Stalenhoef, AFH
    Wilpshaar, W
    Rose, H
    Sager, P
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 79 - 79
  • [35] Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: Results of the andromeda study
    Betteridge, D
    Gibson, M
    ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 107 - 108
  • [36] Percent LDL-C reduction & NCEP-III goal attainment with ezetimibe/simvastatin vs atorvastatin titration in chd/diabetic patients not at goal
    Vieira, J. L.
    Davies, G. M.
    Alemao, E.
    Yin, D.
    Cook, J.
    Moriguchi, E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 557 - 557
  • [37] Percentage LDL-C reduction and NCEP-III goal attainment in a CHD/diabetic patient cohort initiated on ezetimibe/simvastatin vs atorvastatin
    Vieira, J. L.
    Davies, G. M.
    Yin, D.
    Alemao, E.
    Cook, J.
    Moriguchi, E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 556 - 556
  • [38] Association of LDL-C/HDL-C ratio with coronary heart disease: A meta-analysis
    Hu, Siqi
    Fan, Hua
    Zhang, Shenghui
    Chen, Chen
    You, Yao
    Wang, Chunyi
    Li, Jie
    Luo, Lin
    Cheng, Yongran
    Zhou, Mengyun
    Zhao, Xuezhi
    Wen, Wen
    Tan, Tao
    Xu, Fangfang
    Fu, Xinyan
    Chen, Juan
    Zhang, Xingwei
    Wang, Mingwei
    Tang, Jiake
    INDIAN HEART JOURNAL, 2024, 76 (02) : 79 - 85
  • [39] Cost of treating to a modified European atherosclerosis society LDL-C target - Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin
    Smith, DG
    Leslie, SJ
    Szucs, TD
    McBride, S
    Campbell, LM
    Calvo, C
    Lecerf, JM
    Fellin, R
    CLINICAL DRUG INVESTIGATION, 1999, 17 (03) : 185 - 193
  • [40] The relationship between LDL-c reduction during statin therapy and the risk of new-onset diabetes: a meta-analysis
    Cai, R.
    Yuan, Y.
    Wang, S.
    Ruan, X.
    DIABETOLOGIA, 2015, 58 : S565 - S565
12345